Glenmark’s Ryaltris® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age

Our Bureau

Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris® (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), will shortly be available in Austria, Belgium, Czech […]

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

Darmstadt, Germany:    New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to fight infections and develop protective antibodies from vaccines Independent study from Israel showed MAVENCLAD-treated patients receiving COVID-19 vaccine were able to mount antibody response similar to that […]

OZiva Launches Plant-Based Vitamins and Minerals That Focuses on Building Immunity and Providing Holistic Nutrition

Mumbai, Maharashtra, India:  OZiva, India’s leading certified clean and plant-based nutrition, and wellness brand recently announced the launch of its newest range of plant-based vitamins and minerals. Aimed at providing better immunity, gut health, and nutrition, these products provide a revolutionary blend of 100% plant-derived ingredients that are better absorbed […]

LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis

Ballerup, Denmark:  NOT FOR DISTRIBUTION IN THE UK OR IRELAND  If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms1,2 The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials […]

LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021

Ballerup, Denmark & Madison, N.J., United States:    Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients1 Patients enrolled in ECZTRA 1 and 2 parent trials who continued into ECZTEND have now been treated with tralokinumab for two […]

Subscribe Now